Randomized phase III trial of aumolertinib (HS-10296, Au) versus gefitinib (G) as first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and EGFR exon 19 del or L858R mutations (EGFRm).

Shun Lu,Xiaorong Dong,Hong Jian,Jianhua Chen,Gongyan Chen,Yuping Sun,Yinghua Ji,Ziping Wang,Jianhua Shi,Junguo Lu,Shaoshui Chen,Guojun Zhang,Dongqing Lv,Chunling Liu,Juan Li,Xinmin Yu,Zhong Lin,Zhuang Yu,Zhehai Wang,Jiuwei Cui

Randomized phase III trial of aumolertinib (HS-10296, Au) versus gefitinib (G) as first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and EGFR exon 19 del or L858R mutations (EGFRm).

2021

9013Background: Au is a novel, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) with favorable pharmacologic properties that selectively inhibits both EGFR sensiti...

Keywords:

locally advanced
Cancer research
Gefitinib
Medicine
Exon
first line treatment
non-small cell lung cancer (NSCLC)
egfr tki
epidermal growth factor receptor tyrosine kinase

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations